Patent intelligence · US
US 11702473
Site-specific antibody-drug conjugates
Site-specific antibody-drug conjugates
Patent details — US 11702473
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2023
- Expiration
- Jul 13, 2043
- Applicant
- ADC THERAPEUTICS SA
- Claims
- 10
- CPC classes
- A61K, A61K47/68035, A61K47/6867, A61P
Quick answer
US 11702473 (Site-specific antibody-drug conjugates) is held by ADC THERAPEUTICS SA. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ADC THERAPEUTICS SA
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K47/68035, A61K47/6867, A61P, A61P35/02
More from ADC THERAPEUTICS SA
Related pharmaceutical patents in our USPTO index.
-
US 11976122
Anti-IL13Rα2 antibodies
granted -
US 11938192
Dosage regimes for the administration of an anti-CD19 ADC
granted -
US 11813335
Pyrrolobenzodiazepine-antibody conjugates
granted -
US 11690918
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
granted -
US 11596696
Combination therapy with an anti-CD25 antibody-drug conjugate
granted -
US 11426467
Dosage regimes for the administration of an anti-CD25 ADC
granted -
US 11384098
Pyrrolobenzodiazepine-antibody conjugates
granted
Frequently asked questions
What is US patent 11702473?
US 11702473 (Site-specific antibody-drug conjugates) is held by ADC THERAPEUTICS SA. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11702473?
ADC THERAPEUTICS SA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 11702473 expire?
Our index shows an expiration date of Jul 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.